§ 01 Overview
Overview
Dual GLP-1 / glucagon receptor agonist showing strong weight loss and metabolic effects in late-stage trials, particularly in Asian populations.
Approved in China in 2025 for obesity and T2D. Ongoing trials in Western markets.
§ 02 Mechanism
Mechanism of action
Mazdutide activates both GLP-1 and glucagon receptors. The glucagon arm is hypothesized to increase energy expenditure and improve hepatic lipid handling, while GLP-1 drives appetite suppression and glycemic control.
- 01Substantial weight loss in Phase III (GLORY-1)
- 02Improvements in hepatic fat and liver enzymes
- 03Glycemic improvements in T2D
§ 03 Dosing
Dosing protocol
Standard Protocol
- Vial
- 10 mg
- BAC Water
- 1 ml BAC water
- Dose Range
- 3 – 9 mg weekly
- Starting Dose
- 3 mg weekly
- Route
- SubQ
- Frequency
- Weekly
- Cycle
- Titrate every 4 weeks.
§ 04 Evidence
Evidence & research
Approved in China in 2025 for obesity and T2D. Ongoing trials in Western markets.
FDA Status
Not FDA-approved. Approved in China (2025).
§ 06 News
In the news
8 articles from the last 12 months · updates hourly
OPK Raises $125 Million Against Royalties: What Investors Should Know - Eastern Progress
OPK Raises $125 Million Against Royalties: What Investors Should Know Eastern Progress
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties - TradingView
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties TradingView
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties - Yahoo Finance
OPKO Health Secures $125 Million Financing Against Mazdutide Royalties Yahoo Finance
OPKO Health draws $125M against mazdutide royalties in KKR-linked deal - app.dealroom.co
OPKO Health draws $125M against mazdutide royalties in KKR-linked deal app.dealroom.co
OPKO Health Raises $125M Through Senior Secured Notes Backed by Mazdutide Royalties - Kalkine Media
OPKO Health Raises $125M Through Senior Secured Notes Backed by Mazdutide Royalties Kalkine Media
OPKO Health Issues Additional $125 Million in Senior Notes Secured by Mazdutide Royalties - marketscreener.com
OPKO Health Issues Additional $125 Million in Senior Notes Secured by Mazdutide Royalties marketscreener.com
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests - Yahoo Finance
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests Yahoo Finance
OPKO Issues $125M Notes While Keeping Future Mazdutide Royalties - Stock Titan
OPKO Issues $125M Notes While Keeping Future Mazdutide Royalties Stock Titan
§ 07 Sourcing
Sourcing & supply
Regulatory status
Investigational, no compounding path
Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.
Research-use-only · 2
Swiss Chems
Established SARMs/peptide vendor. FDA warning letter Dec 2024 for GLP-1s. Weaker peptide QC than SARMs QC.
Summit Research
FDA warning letter December 2024 across multiple GLP-1s.
Listings are informational, not endorsement. Verify credentials and flags against FDA and PCAB databases before purchasing. Full directory & how to verify →
§ 09 Safety
Safety & side effects
Side effects
- 01Nausea
- 02GI effects typical of incretin class
Contraindications
None specified.
§ 10 Questions
Mazdutide FAQ
- What is Mazdutide?
- Dual GLP-1 / glucagon receptor agonist showing strong weight loss and metabolic effects in late-stage trials, particularly in Asian populations. Mazdutide activates both GLP-1 and glucagon receptors. The glucagon arm is hypothesized to increase energy expenditure and improve hepatic lipid handling, while GLP-1 drives appetite suppression and glycemic control.
- What is Mazdutide used for?
- Reported uses include substantial weight loss in phase iii (glory-1), improvements in hepatic fat and liver enzymes, and glycemic improvements in t2d. Evidence strength is rated Clinical — see the evidence section for detail.
- How is Mazdutide dosed?
- Commonly referenced dosing is 3 – 9 mg weekly, administered SubQ. This is educational reference only; consult a licensed clinician before use.
- How do you reconstitute Mazdutide?
- For Mazdutide, vials commonly come in 10 mg and a common reconstitution is 1 ml BAC water. Use the reconstitution calculator to convert any vial size and water volume into exact insulin-syringe units.
- What are the side effects of Mazdutide?
- Commonly reported side effects include nausea and gi effects typical of incretin class. This list is not exhaustive.
- Is Mazdutide legal?
- Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk. FDA status: Not FDA-approved. Approved in China (2025)..